Modern oHCM Management: Earlier Diagnosis and Cardiac Myosin Inhibitors

Obstructive hypertrophic cardiomyopathy(oHCM)is increasingly recognized earlier in the disease course, and treatment goals have evolved beyond simple symptom relief toward optimization of left ventricular outflow tract (LVOT) gradient, functional capacity, and preservation of systolic function.

In this context, Matthew Martinez, MD, highlights how cardiac myosin inhibitors have reshaped long-term management, shifting clinicians away from waiting for New York Heart Association class III or IV symptoms before intervening. Instead, the focus is now on achieving minimal or absent obstruction and enabling patients to maintain a high quality of life with minimal activity limitations.

Mariko Harper, MD, describes a marked increase in early referrals and the use of cardiac myosin inhibitors as once-daily oral therapies that can be introduced before patients develop debilitating symptoms. Both experts stress that many patients labeled “asymptomatic” in chart documentation demonstrate functional limitations when formally assessed, particularly younger patients who may normalize chronic exertional intolerance. To better delineate symptoms, they routinely employ stress echocardiography and cardiopulmonary exercise testing, which frequently reveal objective impairment despite a subjective report of minimal or no symptoms.

In this discussion, Martinez and Harper underscore long-term care in oHCM now demands proactive identification of patients with latent functional compromise and hemodynamically significant gradients. The conversation frames cardiac myosin inhibitors as central agents in modern management, integrated with advanced physiologic testing to more accurately classify symptom status and tailor treatment intensity over time. This segment serves as a foundational overview of how expert centers are redefining “asymptomatic” disease and reorienting management toward earlier and more precise intervention.